Ketamine in severe acute asthma Sir We recently treated a 35-year-old female asthmatic patient with intravenous bolus ketamine. She is known to be steroid dependent and her prednisolone had been ill-advisedly stopped. She arrived at hospital in severe status asthmaticus and failed to respond in the emergency room to nebulized salbutamol, intravenous aminophylline and hydrocortisone, and blood gases deteriorated. One hour after initiating therapy it was decided to ventilate her mechanically and blood gases improved as a result. However, with the patient very restless and peak airway pressures reaching 60-80cm H20, ketamine was given by intravenous bolus with the aim of achieving sedation without compromising cardiovascular parameters. We were also aware of a report in which ketamine had been used successfully in the treatment of bronchospasm. Peak airway pressures dropped to 40 cm H20 and it was necessary to give two more smaller bolus doses of ketamine over the next 75 min. What subsequently impressed us was the fact that it was possible to extubate her after only 31/4h, before any effect from the hydrocortisone, administered 41/2 h earlier, would have been expected. She subsequently made an uneventful recovery.
This has led us to question whether ketamine might have a wider role in the treatment of severe acute asthma, given that asthmatic deaths have been increasing in recent years (Burrey, 1974; Jackson et al., 1982) , and that a significant number of these still occur in hospital (Sears et al., 1985; Rothwell et al., 1987) where it has been shown that management is variable and treatment sometimes delayed due to the severity of the attack being underestimated (Rothwell et al., 1987; Bucknall et al., 1988) .
Ketamine has known bronchodilator effects, although its mechanism of action is unclear (White et al., 1982) , and it has been implicated as beneficial in the treatment of bronchospasm in the elderly (Sheref, 1985) , the young (Belts et al., 1971; Fisher, 1977; Strube et al., 1986) , by continuous infusion (Sheref, 1985; Strube et al., 1986; Park et al., 1987 ), in ventilated (Fisher, 1977 Rajanna et al., 1982; Park et al., 1987) and non-ventilated (Betls et al., 1971; Strube et al., 1986 ) subjects, in asthmatics (Fisher, 1977; Strube et al 1986; Park et al., 1987) and non-asthmatics (Rajanna et al., 1982) . However, no clinical trial has ever been conducted. Although ether has also been shown to benefit severe acute asthma (Robertson et al., 1985) this is neither widely available nor easily administered, and is less free of side effects. 
